High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Adults With De Novo Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis With Trial Sequential Analysis
In brief
High-flow oxygen was linked to 12% fewer intubations, but evidence remains inconclusive
Across 13 randomized trials involving 4,294 adults with acute hypoxemic respiratory failure, high-flow nasal oxygen was associated with a 12% lower risk of intubation than conventional oxygen. It did not reduce deaths, and trial sequential analysis found the evidence insufficient to confirm an effect on either outcome; the clinical value of a small reduction in hospital stay is also uncertain.
- Journal
- Critical care medicine (Q1)
- Published
- 18 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Ping Lin, Xiaoqian Li, Yu Wang, Zongan Liang, Ting Wang
- PMID
- 43049460
- DOI
- 10.1097/CCM.0000000000007451
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (paper of the day, 19 November 2026): Comparative evidence on HFNC and intubation in acute hypoxemic failure
Abstract
OBJECTIVES: To evaluate the efficacy of high-flow nasal cannula (HFNC) compared with conventional oxygen therapy (COT) in adults with de novo acute hypoxemic respiratory failure (AHRF) using a meta-analysis with trial sequential analysis (TSA). DATA SOURCES: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from database inception to April 7, 2026. STUDY SELECTION: Randomized controlled trials (RCTs) comparing HFNC with COT in adults with de novo AHRF. DATA EXTRACTION: Two investigators independently performed study selection, data extraction, risk-of-bias assessment, and certainty assessment, with discrepancies resolved through discussion. DATA SYNTHESIS: A total of 13 RCTs involving 4294 patients were included in the analysis. Compared with COT, HFNC was associated with a lower risk of intubation (Risk ratio [RR], 0.88; 95% CI, 0.78-0.99; low certainty), but not mortality (RR, 0.96; 95% CI, 0.83-1.10; moderate certainty). TSA indicated that the cumulative evidence was insufficient to establish a conclusive effect for either outcome. Although HFNC was associated with a statistically significant reduction in hospital length of stay (mean difference, -0.84 d; 95% CI, -1.26 to -0.43; low certainty), the clinical importance of this reduction remains uncertain. No significant differences were observed in escalation of therapy (RR, 0.87; 95% CI, 0.75-1.01; very low certainty), ICU admission (RR, 0.84; 95% CI, 0.50-1.39; very low certainty), or ICU length of stay (mean difference, -0.10 d; 95% CI, -0.82 to 0.61; very low certainty). CONCLUSIONS: In adults with de novo AHRF, HFNC may reduce the need for endotracheal intubation but probably does not improve survival compared with COT.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.